Embryonic stem and haematopoietic progenitor cells resist to Aβ oligomer toxicity and maintain the differentiation potency in culture

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–596.
   PubMed Web of Science ®Google Scholar
• Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 2003;81:678–699.
   PubMed Web of Science ®Google Scholar
• Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006;75:333–366.
   PubMed Web of Science ®Google Scholar
• Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416:507–511.
   PubMed Web of Science ®Google Scholar
• Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science 2003;300:486–489.
   PubMed Web of Science ®Google Scholar
• Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, Dobson CM, Stefani M. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 2006;26:8160–8167.
   PubMed Web of Science ®Google Scholar
• Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009;106:4012–4017.
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol 2008;19(suppl 4):iv63–iv66.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 2005;38:911–921.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254–259.
   PubMed Web of Science ®Google Scholar
• Foster JK, Verdile G, Bates KA, Martins RN. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential? Mol Psychiatry 2009;14:239–251.
   PubMed Web of Science ®Google Scholar
• Rando TA. Stem cells, ageing and the quest for immortality. Nature 2006;441:1080–1086.
   PubMed Web of Science ®Google Scholar
• Tang J, Xu H, Fan X, Li D, Rancourt D, Zhou G, Li Z, Yang L. Embryonic stem cell-derived neural precursor cells improve memory dysfunction in Abeta(1–40) injured rats. Neurosci Res 2008;62:86–96.
   PubMed Web of Science ®Google Scholar
• Tarella C, Rutella S, Gualandi F, Melazzini M, Scimè R, Petrini M, Moglia C, Ulla M, Omedé P, Bella VL, Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte colony stimulating-factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy 2010;12:50–59.
   PubMed Web of Science ®Google Scholar
• Harris DT. Non-hematological uses of cord blood. Br J Haematol 2009;147:177–84.
   PubMed Web of Science ®Google Scholar
• Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, M'Hamdi H, Thalji T, Welsh JP, Marley SB, Characterization and clinical applications of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte clony stimulating factor. Stem Cells 2006;24:1822–1830.
   PubMed Web of Science ®Google Scholar
• Habib NA, Gordon MY. Clinical applications of stem cell therapy: the pros and cons of stem cell sources. Regen Med 2006;1:301–302.
   PubMed Web of Science ®Google Scholar
• Cecchi C, Baglioni S, Fiorillo C, Pensalfini A, Liguri G, Nosi D, Rigacci S, Bucciantini M, Stefani M. Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates. J Cell Sci 2005;118:3459–3470.
   PubMed Web of Science ®Google Scholar
• Cecchi C, Pensalfini A, Stefani M, Baglioni S, Fiorillo C, Cappadona S, Caporale R, Nosi D, Ruggiero M, Liguri G. Replicating neuroblastoma cells in different cell-cycle phases display different vulnerability to amyloid toxicity. J Mol Med 2008;86:197–209.
   PubMed Web of Science ®Google Scholar
• Cecchi C, Rosati F, Pensalfini A, Formigli L, Nosi D, Liguri G, Dichiara F, Morello M, Danza G, Pieraccini G, Seladin-1/dhcr24 protects neuroblastoma cells against aβ toxicity by increasing membrane cholesterol content. J Cell Mol Med 2008;12:1990–2002.
   PubMed Web of Science ®Google Scholar
• Rigacci S, Bucciantini M, Relini A, Pesce A, Gliozzi A, Berti A, Stefani M. The (1–63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys J 2008;94:3635–3646.
   PubMed Web of Science ®Google Scholar
• Neri T, Merico V, Garagna S, Redi CA, Zuccotti M. Expression of phase I and phase II genes in mouse embryonic stem cells cultured in the presence of 2,3,7,8-tetrachlorodibenzo-para-dioxin. Biochim Biophys Acta 2008;1780:826–836.
   PubMed Web of Science ®Google Scholar
• Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Self-assembly of Abeta(1–42) into globular neurotoxins. Biochemistry 2003;42:12749–12760.
   PubMed Web of Science ®Google Scholar
• Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol 2001;17:387–403.
   PubMed Web of Science ®Google Scholar
• Bucciantini M, Rigacci S, Berti A, Pieri L, Cecchi C, Nosi D, Formigli L, Chiti F, Stefani M. Patterns of cell death triggered in two different cell lines by HypF-N pre-fibrillar aggregates. FASEB J 2005;19:437–439.
   PubMedGoogle Scholar
• Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609–619.
   PubMed Web of Science ®Google Scholar
• Kumar S. Caspase function in programmed cell death. Cell Death Differ 2007;14:32–43.
   PubMed Web of Science ®Google Scholar
• Yankner BA, Duffy LK, Kinschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990;250:279–282.
   PubMed Web of Science ®Google Scholar
• López-Toledano MA, Shelanski ML. Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J Neurosci 2004;24:5439–5444.
   PubMed Web of Science ®Google Scholar
• Eucher JN, Uemura E, Sakaguchi DS, Greenlee MH. Amyloid-beta peptide affects viability but not differentiation of embryonic and adult rat hippocampal progenitor cells. Exp Neurol 2007;203:486–492.
   PubMed Web of Science ®Google Scholar
• Haughey NJ, Liu D, Nath A, Borchard AC, Mattson MP. Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med 2002;1:125–135.
   PubMed Web of Science ®Google Scholar
• Mazur-Kolecka B, Golabek A, Nowicki K, Flory M, Frackowiak J. Amyloid-beta impairs development of neuronal progenitor cells by oxidative mechanisms. Neurobiol Aging 2006;27:1181–1192.
   PubMed Web of Science ®Google Scholar
• Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 1993;303:474–482.
   PubMed Web of Science ®Google Scholar
• Kim H, Yoon SC, Lee TY, Jeong D. Discriminative cytotoxicity assessment based on various cellular damages. Toxicol Lett 2009;184:13–17.
   PubMed Web of Science ®Google Scholar
• Butterfield DA. Amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 2002;36:1307–1313.
   PubMed Web of Science ®Google Scholar
• Abe K, Saito H. Both oxidative stress-dependent and independent effects of amyloid beta protein are detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Brain Res 1999;830:146–154.
   PubMed Web of Science ®Google Scholar
• Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590–8607.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Ariga T, Yu RK. Cytotoxic effects of G(M1) ganglioside and amyloid beta-peptide on mouse embryonic neural stem cells. ASN Neuro 2010;2:e00029.
   Web of Science ®Google Scholar
• Jan A, Gokce O, Luthi-Carter R, Lashuel HA. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem 2008;283:28176–28189.
   PubMed Web of Science ®Google Scholar